Abstract:Background: The chromodomain helicase DNA-binding protein 2 (CHD2) gene, is an ATPase and part of the CHD family of chromatin remodelers. Mutations in the CHD2 gene are inherited in an autosomal-dominant manner and can lead to intellectual disability, epilepsy, and autism. We investigated the clinical characteristics of CHD2-related conditions and their possible pathogenesis. Methods: We collected and analysed the clinical data of patients that were identified as having CHD2 mutations. Genetic testing was performed using targeted sequencing or whole-exome sequencing. We analysed the expression of CHD2 and repressor element 1-silencing transcription factor (REST) in blood samples using quantitative PCR and the conservation of the mutations. The CHD2 mutations we identified were compared with the known mutations reported in the CHD2-related literature. Results: Eight patients with CHD2 gene mutations were analysed. Six mutations were identified; four were unreported previously (c.670C>T; c.4012A>C; c.2416dup; c.1727-1728insAT), and two were known mutations: c.5035C>T (two cases) and c.4173dup (two cases). Among these mutations, seven were de novo mutations, and one could not be determined because the parents refused genetic testing. The clinical manifestations included mild or severe intellectual disability, epilepsy, and behavioural abnormalities. Quantitative PCR showed that the CHD2 gene expression levels among the patients, parents, and the controls were not significantly different. The levels of REST gene expression in the patients were significantly higher than those of the controls; thus, mutation of the CHD2 gene led to an increase in the expression level of the REST gene. The mutations reported were all located in conserved positions in different species. Among the various medications administered for treatment, valproate showed the best results for the treatment of epilepsy caused by CHD2 gene mutation. Conclusion: Mutation in CHD2 did not lead to a significant decrease in its expression level, indicating that the clinical phenotype was unrelated to its expression level, and the mutant protein may retain some function. Most of the mutations relatively stable. In addition, the clinical manifestations from the same mutation in the CHD2 gene were different among the known cases; this may be related to the regulation of REST or other regulatory factors.

CHD2 mutations in Lennox-Gastaut syndrome

[Clinical and Genetic Analyses of a Family with Atypical Nonketotic Hyperglycinemia Caused by Compound Heterozygous Mutations in the GLDC Gene].

CHD2‐related Epilepsy: Novel Mutations and New Phenotypes

Autosomal Dominant Sleep-Related Hypermotor Epilepsy Associated with a Novel Mutation of KCNT1.

Expanding the Mutational Landscape and Clinical Phenotype of CHD2-Related Encephalopathy

Clinical analysis of CHD2 gene mutations in pediatric patients with epilepsy

CHD2-Related CNS Pathologies

Clinical analysis of five CHD2 gene mutations in Chinese children with epilepsy

Clinical Study of 8 Cases of <i>CHD2</i> Gene Mutation-Related Neurological Diseases and Their Mechanisms

A Novel Variant of the CHD2 Gene Associated With Developmental Delay and Myoclonic Epilepsy

Clinical Study of 8 Cases of CHD2 Gene Mutation-Related Neurological Diseases and Their Mechanisms

Novel Loss-of-Function Variants in CHD2 Cause Childhood-Onset Epileptic Encephalopathy in Chinese Patients

CHD2 haploinsufficiency is associated with developmental delay, intellectual disability, epilepsy and neurobehavioural problems

GUCY2D Gene Loss-of-Function Mutations Responsible for Leber Congenital Amaurosis 1

CHD2-epilepsy: Polygraphic documentation of self-induced seizures due to fixation-off sensitivity

A novel de novo frameshift variant in the CHD2 gene related to intellectual and developmental disability, seizures and speech problems

Mutation update on the CHD7 gene involved in CHARGE syndrome

Juvenile myoclonic epilepsy mimic associated with CHD2 gene mutation

Clinical features and underlying etiology of children with Lennox-Gastaut syndrome

CHD2 pathogenic nonsense variant in a three-generation family with variable phenotype and a paracentric inversion 16: Case report

Whole Genome Sequencing Identifies Novel Compound Heterozygous Lysosomal Trafficking Regulator Gene Mutations Associated with Autosomal Recessive Chediak-Higashi Syndrome